{
    "root": "5eb0e4a7-f749-4308-8873-efba1717a0c6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KEVZARA",
    "value": "20250516",
    "ingredients": [
        {
            "name": "SARILUMAB",
            "code": "NU90V55F8I"
        },
        {
            "name": "ARGININE",
            "code": "94ZLA3W45F"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "KEVZARA Â® is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). ( 1.1 ) adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. ( 1.2 ) patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA). ( 1.3 )",
    "contraindications": "General Considerations for Administration KEVZARA initiation is not recommended in patients with ANC less than 2,000/mm 3 , platelets less than 150,000/mm 3 or liver transaminases above 1.5 times ULN. See Full Prescribing Information (FPI) for complete information. ( 2.1 ) Recommended Dosage in RA The recommended dosage is 200 mg subcutaneously, once every 2 weeks. ( 2.2 ) For RA, KEVZARA may be used as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs. ( 2.2 ) Recommended Dosage in PMR The recommended dosage is 200 mg subcutaneously, once every two weeks   in combination with a tapering course of corticosteroids. ( 2.3 ) For PMR, KEVZARA can be used as monotherapy following discontinuation of corticosteroids. ( 2.3 ) Recommended Dosage in pJIA The recommended dosage is 200 mg given subcutaneously once every 2 weeks for pJIA patients who weigh 63 kg or greater using the 200 mg/1.14 mL pre-filled syringe. ( 2.4 ) For pJIA, KEVZARA can be used as monotherapy or in combination with conventional DMARDs. ( 2.4 ) Dosage Modifications for Cytopenias, Abnormal Liver Enzymes, Infections See FPI for complete information. ( 2.6 )",
    "warningsAndPrecautions": "KEVZARA (sarilumab) injection is supplied as a clear and colorless to pale yellow solution in single-dose pre-filled syringes, and single-dose pre-filled pens.\n                  \n                     \n                     \n                     \n                     \n                        \n                           Strength\n                           Package Size\n                           NDC Number\n                        \n                     \n                     \n                        \n                           150 mg/1.14 mL\n                           2 syringes per pack\n                           0024-5908-01\n                        \n                        \n                           200 mg/1.14 mL\n                           2 syringes per pack\n                           0024-5910-01\n                        \n                     \n                  \n                  \n                     \n                     \n                     \n                     \n                        \n                           Strength\n                           Package Size\n                           NDC Number\n                        \n                     \n                     \n                        \n                           150 mg/1.14 mL\n                           2 pre-filled pens per pack\n                           0024-5920-01\n                        \n                        \n                           200 mg/1.14 mL\n                           2 pre-filled pens per pack\n                           0024-5922-01",
    "adverseReactions": "KEVZARA is contraindicated in patients with known hypersensitivity to sarilumab or any of the inactive ingredients [see Warnings and Precautions (5.5) and Adverse Reactions (6.1)]."
}